pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
236
stories
Aug 6, 26
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
Aug 6, 26
STAT+: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and more
stat
Aug 6, 26
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
Aug 6, 26
Cardiac drug developer Braveheart banks more than $382M in IPO
biopharma dive
Aug 6, 26
Recon: FDA approves first drug for type 1 narcolepsy, mRNA flu vaccine; No merger talks between AstraZeneca-BMS
raps
Aug 5, 26
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
stat
Aug 5, 26
Merger talks between AstraZeneca, Bristol Myers are off — report
endpoints
Aug 5, 26
A COPD drug from China draws $115M in venture funding
biopharma dive
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 5, 26
5 NextGen winners who went public this year (and which ones are hiring)
biospace
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 4, 26
Icon inks Anthropic partnership to deploy Claude into clinical trials
fiercebiotech
Aug 4, 26
STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
stat
Aug 4, 26
STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
stat
Aug 4, 26
Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?
endpoints
Aug 3, 26
STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case
stat
Aug 3, 26
Biopharma industry questions potential AstraZeneca, Bristol Myers merger
endpoints
Aug 3, 26
Michigan reports the first 2 U.S. deaths related to a diarrhea-causing parasite
stat
Aug 3, 26
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
Aug 3, 26
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
Aug 3, 26
STAT+: Medicare eliminates key pathways used by ‘breakthrough’ devices for extra payments
stat
Aug 3, 26
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
biospace
Aug 3, 26
STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
stat
Aug 3, 26
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Aug 3, 26
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Aug 3, 26
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
← prev
page 4 of 8
next →
